查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870506

抗风湿药物市场按药物类别、给药途径、类型、疾病类型和分销管道划分－2025-2032年全球预测

Anti-Rheumatics Market by Drug Class, Route Of Administration, Type, Disease Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，抗风湿药物市场规模将达到 1,522.8 亿美元，复合年增长率为 5.85%。

关键市场统计数据
基准年 2024 965.6亿美元
预计年份：2025年 1019.5亿美元
预测年份 2032 1522.8亿美元
复合年增长率 (%) 5.85%

一个简洁而具有策略意义的框架，阐述了影响当代抗风湿药物环境和决策重点的临床、监管和商业性驱动因素。

抗风湿治疗领域处于复杂免疫学、不断发展的治疗方法和不断变化的医疗服务模式的交汇点。本导言提炼了构成当前格局的基本临床和商业性特征，重点阐述了决策者需要考虑的关键驱动因素。它着重介绍了缓解疾病抗风湿药物（DMARDs）的创新、靶向生物製药和小分子药物的成熟以及以患者为中心的治疗路径的进步如何共同重塑临床实践和商业策略。

标靶治疗、生物标记驱动的精准医疗方法以及给药创新的进展将如何重新定义风湿病的临床实践和治疗可及性

抗风湿药物领域正经历一场变革，其驱动力包括科学突破、治疗方法的持续演进以及精准医疗与价值医疗的融合。免疫学和分子生物学的进步正在加速从广谱抗发炎药物转变为标靶疾病修正治疗的转变，这些疗法旨在改变疾病进程，而不仅仅是控制症状。这种转变凸显了基于生物标记的患者筛选和伴随诊断技术开发的重要性，以优化临床疗效。

对2025年实施的美国关税调整以及产业相关人员采取的策略缓解措施的累积营运和供应链影响进行评估

2025年实施的新关税政策带来了复杂的贸易和成本考量，影响供应链、生产投入和跨境分销。这些关税变化促使各组织重新评估筹资策略，并考虑其对下游契约製造安排的影响。因此，製造商和采购团队已开始评估替代供应基础、多源采购策略和近岸外包方案，以降低跨境成本上涨的风险。

基于对治疗领域、作用机制、给药途径、疾病适应症、产品类型和分销管道的全面細項分析，制定有针对性的策略。

深度細項分析揭示了抗风湿治疗领域固有的临床和商业性复杂性，为产品和组合策略提供了坚实的基础。依药物类别划分，该领域包括皮质类固醇、缓解疾病抗风湿药（DMARDs）、非类固醇消炎剂（NSAIDs）和尿酸标靶治疗。其中，缓解疾病风湿药类别又进一步细分为生物製剂DMARDs、传统DMARDs和标靶合成DMARDs。在生物製剂DMARDs中，根据作用机制，此领域可进一步细分为B细胞抑制剂、白细胞介素抑制剂、T细胞共刺激调节剂和肿瘤坏死因子抑制剂等亚组，每种亚组在疗效、安全性和市场进入方面均存在差异。

美洲、欧洲、中东和非洲以及亚太地区的临床、监管和市场准入趋势将如何影响差异化商业化和实证策略

区域趋势对风湿病治疗领域的临床应用、监管策略和商业性化进程有显着影响。美洲地区的特点是临床研发活动活跃，高度重视以支付主导的价值论证，并拥有众多风湿病治疗领域的卓越中心。因此，美洲地区的商业化策略往往优先考虑高品质的比较证据和核准后真实世界研究，以指南医保报销谈判和专科药房整合。

竞争优势源自于整合开发能力、真实世界证据计画、病患支持创新、以及加速产品推广的策略伙伴关係。

抗风湿领域的竞争格局呈现出现有旗舰产品、新一代生物製剂和新兴标靶治疗并存的局面，多家成熟的製药公司在多个治疗领域发挥主导作用。这些公司兼具深厚的免疫学专业知识、全球研发能力、广泛的商业性覆盖率和丰富的健保支付方合作经验。此外，专注于特定领域的生物製药公司和创新计画不断推出挑战现有治疗模式的新型作用机制，为策略伙伴关係创造了机会。

领导者应采取切实可行的优先行动，以使临床创新与支付方要求、供应弹性、病人参与和合作伙伴关係保持一致。

产业领导者应采取行动导向策略，将科学创新与切实可行的准入计画和业务永续营运结合。首先，将卫生经济学和结果研究纳入二期和三期临床试验通讯协定，优先考虑临床开发与支付方证据要求的一致性，从而减少后期阶段的准入障碍。儘早并持续地与关键意见领袖和支付相关人员沟通，将有助于完善终点指标、优化比较试验设计，并制定反映实际需求的报销理由。

采用严谨、透明且多维度的调查方法，整合相关利益者访谈、临床文献综述和专家检验，以得出可操作的策略洞见。

本分析所依据的研究结合了定性和定量数据，并采用多层次调查方法，以确保研究结果的稳健性和可重复性。主要研究包括对临床专家、行业高管、监管专家和支付方进行结构化访谈，以收集关于治疗创新、准入挑战和营运限制的第一手资料。此外，还对同行评审的临床研究、监管指导文件和已发布的药品申请文件进行了二次文献综述，以验证临床和政策趋势。

策略综合分析强调，需要整合证据产生、保障供应弹性以及製定区域准入策略，才能充分发挥不断发展的抗风湿疗法的潜力。

总之，由于治疗方法创新、不断变化的用药途径以及日益复杂的供应链，抗风湿药物生态系统正在经历重大变革。生物製药推动了治疗策略从症状管理到标靶缓解疾病的转变，这既展现了临床应用前景，也带来了策略上的复杂性。积极整合支付方驱动的证据生成、以患者为中心的服务模式以及稳健的营运策略的相关人员，将更有能力把科学进步转化为可及且永续的治疗方案。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 透过整合基于患者基因标记的个人化生物疗法来优化类风湿性关节炎的治疗
  • 扩大英夫利西单抗和EtanerceptInfliximab产品的范围，以解决新兴市场的可负担性问题
  • 引入远端医疗和远端监测平台，用于早期发现类风湿性关节炎急性发作
  • 开发一种口服生物利用度高的JAK抑制剂，针对类风湿性关节炎中的多种发炎通路
  • 一项评估IL-17抑制剂和TNF抑制剂联合治疗治疗难治性干癣性关节炎的临床试验
  • 新的真实世界证据表明，新一代抗风湿药物具有良好的长期安全性。
  • 利用以患者为中心的数位健康工具来提高抗风湿治疗方法的依从性

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：抗风湿药物市场（依药物类别划分）

  • 皮质类固醇
  • 缓解疾病抗风湿药物
    • 生物DMARDs
      • B细胞抑制剂
      • 白细胞介素抑制剂
      • T细胞共刺激调节剂
      • 肿瘤坏死因子（TNF）抑制剂
    • 传统DMARDs
    • 标靶定向DMARDs
  • 非类固醇消炎剂
  • 尿酸药物

9. 依给药途径分類的抗风湿药物市场

  • 注射
  • 口服
  • 外用药物

第十章 抗风湿药物市场（依类型划分）

  • 非处方药
  • 处方药

第十一章 依疾病类型分類的抗风湿药物市场

  • 僵直性脊椎炎
  • 黏液囊炎
  • 痛风
  • 幼年特发性关节炎
  • 骨关节炎
  • 骨质疏鬆症
  • 多发性肌痛
  • 干癣性关节炎
  • 类风湿性关节炎
  • 修格兰氏症候群
  • 全身性红斑性狼疮
  • 全身性硬化症/硬皮症
  • 肌腱炎

第十二章 抗风湿药物市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：各地区抗风湿药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 抗风湿药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国抗风湿药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AbbVie Inc.
    • Alvotech
    • Amgen Inc.
    • ANI Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • CH Boehringer Sohn AG & Co. KG
    • DeepCure
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Fresenius Kabi AG
    • Galapagos NV
    • Gilead Sciences, Inc.
    • GlaxoSmithKline PLC
    • ILTOO Pharma SAS
    • Johnson & Johnson Services Inc.
    • medac GmbH
    • Merck & Co., Inc.
    • Novartis AG
    • Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
    • Pfizer, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • UCB SA
    • Vertex Pharmaceuticals Incorporated
Product Code: MRR-1A1A064C0147

The Anti-Rheumatics Market is projected to grow by USD 152.28 billion at a CAGR of 5.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 96.56 billion
Estimated Year [2025] USD 101.95 billion
Forecast Year [2032] USD 152.28 billion
CAGR (%) 5.85%

A concise and strategic framing of clinical, regulatory, and commercial drivers that define the contemporary anti-rheumatics environment and decision-making priorities

The anti-rheumatics therapeutic arena sits at the intersection of complex immunology, evolving therapeutic modalities, and shifting healthcare delivery paradigms. This introduction distills the essential clinical and commercial contours that define the current landscape while clarifying the critical drivers that decision-makers must consider. It foregrounds how innovation in disease-modifying agents, the maturation of targeted biologics and small molecules, and heightened patient-centric care pathways are collectively reshaping clinical practice and commercial strategies.

Beyond clinical innovation, regulatory expectations and payer scrutiny continue to influence development priorities and commercialization timelines. As stakeholders increasingly prioritize real-world evidence and cost-effectiveness alongside efficacy and safety, developers and payers must reconcile clinical value with sustainable access models. Consequently, the therapeutic environment demands cross-functional alignment among clinical development teams, health economics specialists, market access strategists, and commercial leaders to translate scientific advances into adoptable treatments.

Finally, the introduction highlights the imperative of agile strategy formulation. Organizations that operationalize robust evidence generation plans, engage early with key opinion leaders and payers, and deploy adaptive commercial approaches will be better positioned to convert scientific progress into meaningful patient outcomes and durable clinical adoption. This framing sets the stage for deeper analysis in subsequent sections that examine transformative shifts, policy impacts, segmentation dynamics, regional variation, competitive positioning, and practical recommendations for leaders.

How advances in targeted therapies, biomarker-driven precision approaches, and delivery innovations are redefining clinical practice and access for rheumatic diseases

The anti-rheumatics landscape is in the midst of transformative shifts driven by scientific breakthroughs, evolving therapeutic modalities, and the convergence of precision medicine with value-based care. Advances in immunology and molecular biology have accelerated the transition from broad-spectrum anti-inflammatories to targeted disease-modifying therapies that aim to alter disease trajectories rather than manage symptoms alone. This shift elevates the importance of biomarker-driven patient selection and the development of companion diagnostics to optimize clinical outcomes.

Concurrently, the therapeutic toolkit is diversifying. Biologic agents continue to mature alongside targeted synthetic disease-modifying therapies, and there is renewed interest in novel mechanisms such as B-cell modulation, interleukin signaling inhibitors, and co-stimulation pathway antagonists. These options, together with optimized small-molecule inhibitors, enable more personalized regimens and combination strategies. As clinical practice incorporates these options, payers and providers demand robust comparative effectiveness and long-term safety data to inform formularies and treatment algorithms.

In parallel, delivery and adherence innovations are reshaping how therapies are administered and experienced by patients. Injectable therapies now coexist with improved oral regimens and localized topical formulations, creating new considerations for patient preference, adherence, and health system logistics. Moreover, the digitalization of care pathways, including telehealth and remote monitoring, is enhancing chronic disease management while imposing new requirements for evidence demonstrating real-world benefit. Taken together, these transformative shifts create both opportunity and complexity for developers and healthcare systems seeking to deliver superior clinical outcomes while ensuring access and affordability.

Assessing the cumulative operational and supply chain consequences of United States tariff adjustments introduced in 2025 and strategic mitigations adopted by industry stakeholders

The implementation of new tariff policies in 2025 introduced a complex set of trade and cost considerations that have implications across research supply chains, manufacturing inputs, and cross-border distribution. These tariff changes amplified the need for organizations to reassess sourcing strategies for active pharmaceutical ingredients, bioprocessing supplies, and specialized packaging, and to consider the downstream impacts on contract manufacturing arrangements. As a consequence, manufacturers and procurement teams have begun to evaluate alternative supply hubs, multi-sourcing approaches, and nearshoring options to mitigate exposure to incremental cross-border costs.

In addition to procurement pressures, tariffs have influenced contract negotiation dynamics with third-party suppliers, prompting renewed emphasis on long-term agreements and cost-sharing provisions that stabilize input pricing. Regulatory filings and international clinical trial operations have also felt the effects, as logistics complexity and import-export compliance requirements impose additional administrative burdens and potential delays. These operational friction points underscore the importance of integrated supply chain visibility and proactive contingency planning.

Importantly, the tariff environment has not affected all stakeholders uniformly. Companies with integrated manufacturing footprints and established regional distribution networks have demonstrated greater resilience, whereas asset-light organizations that rely on single-source international suppliers have faced higher disruption risk. Consequently, strategic responses have included accelerating investments in regional manufacturing, strengthening supplier diversification, and enhancing scenario planning. Looking ahead, sustained attention to trade policy developments and adaptive procurement strategies will remain essential for preserving operational continuity and supporting reliable therapy availability.

Comprehensive segmentation-driven insights across therapeutic classes, mechanisms, administration routes, disease indications, product types, and distribution channels for targeted strategy design

Deep segmentation analysis reveals the clinical and commercial complexity inherent in the anti-rheumatics therapeutic area and provides a robust framework for product and portfolio strategy. Drug class distinctions encompass corticosteroids, disease-modifying anti-rheumatics drugs, nonsteroidal anti-inflammatory drugs, and uric acid-targeted therapies, with the disease-modifying category further disaggregated into biologic DMARDs, conventional DMARDs, and targeted synthetic DMARDs. Within biologic DMARDs, the landscape is nuanced by mechanism-of-action subgroups that include B-cell inhibitors, interleukin inhibitors, T-cell co-stimulation modulators, and tumor necrosis factor inhibitors, each carrying distinct efficacy, safety, and market access implications.

Route-of-administration segmentation differentiates injectable, oral, and topical modalities, a classification that informs adherence strategies, patient preference analysis, and distribution logistics. When considering product type, the distinction between over-the-counter and prescription-based therapies influences regulatory pathways, promotional frameworks, and payer interactions. Disease-type segmentation spans a wide clinical spectrum including ankylosing spondylitis, bursitis, gout, juvenile idiopathic arthritis, osteoarthritis, osteoporosis, polymyalgia rheumatica, psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematosus, systemic sclerosis or scleroderma, and tendinitis, and this diversity necessitates tailored clinical development plans and targeted messaging to distinct clinical specialists.

Finally, distribution channels such as hospital pharmacies, online pharmacies, and retail pharmacies shape access strategies, patient journey mapping, and channel economics. By integrating these segmentation lenses, stakeholders can prioritize development investments, refine value propositions for payers and providers, and design patient support programs that align with both therapeutic modality and end-user preferences. This holistic segmentation approach supports more precise positioning, competitive differentiation, and evidence plans that reflect the heterogeneity of both disease and care delivery.

How regional clinical, regulatory, and access dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shape differentiated commercialization and evidence strategies

Regional dynamics exert a powerful influence on clinical adoption, regulatory approaches, and commercial execution in the anti-rheumatics domain. The Americas region has been characterized by robust clinical development activity, a strong emphasis on payer-driven value demonstration, and established centers of excellence for rheumatology care. As a result, commercialization strategies in the Americas often prioritize high-quality comparative evidence and post-authorization real-world studies that inform reimbursement negotiations and specialty pharmacy integration.

Europe, the Middle East and Africa presents a heterogeneous landscape where regulatory frameworks, health technology assessment processes, and reimbursement criteria vary significantly across jurisdictions. Stakeholders operating across this region must tailor evidence generation and access strategies to meet diverse national requirements, engage proactively with regional key opinion leaders, and navigate complex tendering and formulary processes. Collaboration with local clinical experts and early engagement with assessment bodies can accelerate reimbursement pathways and support uptake.

Asia-Pacific continues to evolve rapidly with varying levels of clinical infrastructure, regulatory sophistication, and payer maturity. Many markets in the region are increasing investments in biologic therapies while simultaneously expanding local manufacturing capabilities and regulatory pathways for biosimilars. Consequently, manufacturers should align regulatory submission strategies, pricing approaches, and patient support models with local market dynamics to ensure sustainable access and adoption. Across all regions, cross-border collaboration, localized evidence generation, and nuanced stakeholder engagement remain central to achieving durable clinical and commercial outcomes.

Competitive advantage is driven by integrated development capabilities, real-world evidence programs, patient support innovations, and strategic partnerships that accelerate adoption

Competitive positioning within the anti-rheumatics arena reflects a mix of legacy franchises, next-generation biologics, and emerging targeted therapies, with several established pharmaceutical companies holding leading roles across multiple therapeutic classes. These organizations pair deep immunology expertise with global development capabilities, broad commercial footprints, and extensive payer engagement experience. Moreover, a set of specialized biopharmaceutical firms and innovator programs continue to introduce novel mechanisms that challenge incumbent therapeutic paradigms and create opportunities for strategic partnerships.

In addition to product portfolios, competitive differentiation increasingly arises from integrated capabilities such as advanced manufacturing, real-world evidence generation, and patient support services that enhance adherence and long-term outcomes. Companies that invest in companion diagnostics, digital health solutions for chronic disease management, and robust pharmacovigilance systems achieve stronger alignment with provider and payer expectations. Strategic alliances, licensing agreements, and selective mergers and acquisitions remain pragmatic paths to complement internal capabilities and accelerate access to promising modalities.

Finally, corporate strategies that prioritize transparent outcomes data, constructive engagement with health technology assessment bodies, and proactive pricing and reimbursement dialogues tend to reduce commercialization friction. As competition intensifies, the ability to demonstrate compelling value across clinical, economic, and humanistic endpoints will determine which therapies achieve sustained adoption and which struggle to secure durable placement within therapeutic guidelines and payer formularies.

Practical and prioritized actions leaders should implement to align clinical innovation with payer requirements, supply resilience, patient engagement, and collaborative partnerships

Industry leaders should adopt an action-oriented agenda that aligns scientific innovation with pragmatic access planning and operational resilience. First, prioritize the alignment of clinical development with payer evidence requirements by embedding health economics and outcomes research into phase II and III protocols, thereby reducing later-stage access friction. Early and continuous engagement with key opinion leaders and payer stakeholders will refine endpoints, inform comparative trial design, and support reimbursement narratives that reflect real-world clinical priorities.

Second, strengthen supply chain resilience through strategic supplier diversification, regional manufacturing investments, and enhanced inventory visibility. These measures help mitigate tariff-related and geopolitical risks while preserving clinical trial continuity and commercial supply. Third, adopt patient-centric commercialization approaches that incorporate route-of-administration preferences, adherence support tools, and digital interventions to improve engagement and long-term outcomes. Tailored patient support programs can also reduce barriers to initiation and sustainment of complex regimens.

Fourth, pursue targeted partnerships that accelerate access to complementary capabilities, including diagnostic developers, specialty pharmacies, and digital health providers. Such collaborations can expand product value propositions and streamline care pathways. Finally, commit to transparent evidence sharing and proactive pricing dialogues with payers and providers to build trust and expedite inclusion in treatment guidelines and formularies. Together, these actions create a coherent strategic posture that balances innovation with access, operational stability, and enduring patient benefit.

A rigorous and transparent multi-method research approach that integrates stakeholder interviews, clinical literature review, and expert validation to produce actionable strategic insights

The research underpinning this analysis synthesized qualitative and quantitative inputs using a layered methodology designed to ensure robustness and reproducibility. Primary research included structured interviews with clinical specialists, industry executives, regulatory experts, and payers to capture first-hand perspectives on therapeutic innovation, access challenges, and operational constraints. These direct insights were complemented by secondary literature review of peer-reviewed clinical studies, regulatory guidance documents, and publicly available pharmaceutical filings to triangulate clinical and policy trends.

Data synthesis relied on thematic analysis to identify consistent signals across stakeholder interviews and document review, supplemented by case-based comparative assessments of therapeutic classes and regional regulatory pathways. Validation workshops with independent clinical experts and commercial leaders provided further scrutiny of key findings and ensured that conclusions reflect practical realities faced by developers and healthcare systems. Throughout the process, careful attention to methodological transparency, bias mitigation, and traceability of sources reinforced the credibility of insights.

Finally, segmentation-driven analyses were performed to align evidence needs with therapeutic modality, route of administration, indication, and distribution channel considerations. This approach supported nuanced recommendations that are actionable across both global strategy and local implementation contexts, while preserving clarity about the assumptions and limitations inherent in qualitative research synthesis.

Strategic synthesis emphasizing the need for integrated evidence generation, supply resilience, and localized access strategies to realize the promise of evolving anti-rheumatics therapies

In conclusion, the anti-rheumatics ecosystem is undergoing substantive change driven by therapeutic innovation, evolving access dynamics, and supply chain complexities. The transition from symptom management toward targeted disease modification, supported by advances in biologics and targeted synthetic agents, presents both clinical promise and strategic complexity. Stakeholders that proactively integrate payer-focused evidence generation, patient-centric delivery models, and resilient operational strategies will be best positioned to translate scientific advances into accessible and sustainable therapeutic options.

Moreover, regional heterogeneity in regulatory expectations and reimbursement mechanisms requires tailored approaches that balance global strategy with local execution. Strategic partnerships, investments in manufacturing and supply chain diversification, and transparent engagement with payers and clinical communities will materially influence the trajectory of adoption. Ultimately, the combination of rigorous clinical evidence, robust real-world data, and collaborative commercialization models offers the most effective pathway to improve outcomes for patients living with rheumatic diseases while ensuring the viability of innovative therapies in complex healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of personalized biologic therapies based on patient genetic markers for rheumatoid arthritis treatment optimization
  • 5.2. Expansion of biosimilar infliximab and etanercept formulations improving affordability in emerging markets
  • 5.3. Adoption of telemedicine and remote monitoring platforms for early detection of rheumatoid arthritis flares
  • 5.4. Development of orally bioavailable JAK inhibitors targeting multiple inflammatory pathways in rheumatoid arthritis
  • 5.5. Clinical trials evaluating combination use of IL-17 and TNF inhibitors for refractory psoriatic arthritis management
  • 5.6. Emerging real-world evidence demonstrating long-term safety profiles of next-generation anti-rheumatic agents
  • 5.7. Implementation of patient-centric digital health tools to improve adherence to anti-rheumatoid treatment regimens

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Rheumatics Market, by Drug Class

  • 8.1. Corticosteroids
  • 8.2. Disease Modifying Anti-rheumatics Drugs
    • 8.2.1. Biologic DMARDs
      • 8.2.1.1. B-cell Inhibitors
      • 8.2.1.2. Interleukin Inhibitors
      • 8.2.1.3. T-cell Co-stimulation Modulators
      • 8.2.1.4. Tumor Necrosis Factor (TNF) Inhibitors
    • 8.2.2. Conventional DMARDs
    • 8.2.3. Targeted Synthetic DMARDs
  • 8.3. Nonsteroidal Anti-inflammatory Drugs
  • 8.4. Uric Acid Drugs

9. Anti-Rheumatics Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical

10. Anti-Rheumatics Market, by Type

  • 10.1. Over-the-Counter Drugs
  • 10.2. Prescription-Based Drugs

11. Anti-Rheumatics Market, by Disease Type

  • 11.1. Ankylosing Spondylitis
  • 11.2. Bursitis
  • 11.3. Gout
  • 11.4. Juvenile Idiopathic Arthritis
  • 11.5. Osteoarthritis
  • 11.6. Osteoporosis
  • 11.7. Polymyalgia Rheumatica
  • 11.8. Psoriatic Arthritis
  • 11.9. Rheumatoid Arthritis
  • 11.10. Sjogren's Syndrome
  • 11.11. Systemic Lupus Erythematosus
  • 11.12. Systemic Sclerosis/Scleroderma
  • 11.13. Tendinitis

12. Anti-Rheumatics Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Anti-Rheumatics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anti-Rheumatics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anti-Rheumatics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. Alvotech
    • 16.3.3. Amgen Inc.
    • 16.3.4. ANI Pharmaceuticals, Inc.
    • 16.3.5. AstraZeneca PLC
    • 16.3.6. Bayer AG
    • 16.3.7. Biogen Inc.
    • 16.3.8. Bristol-Myers Squibb Company
    • 16.3.9. C. H. Boehringer Sohn AG & Co. KG
    • 16.3.10. DeepCure
    • 16.3.11. Eisai Co., Ltd.
    • 16.3.12. Eli Lilly and Company
    • 16.3.13. F. Hoffmann-La Roche Ltd.
    • 16.3.14. Fresenius Kabi AG
    • 16.3.15. Galapagos NV
    • 16.3.16. Gilead Sciences, Inc.
    • 16.3.17. GlaxoSmithKline PLC
    • 16.3.18. ILTOO Pharma SAS
    • 16.3.19. Johnson & Johnson Services Inc.
    • 16.3.20. medac GmbH
    • 16.3.21. Merck & Co., Inc.
    • 16.3.22. Novartis AG
    • 16.3.23. Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
    • 16.3.24. Pfizer, Inc.
    • 16.3.25. Regeneron Pharmaceuticals, Inc.
    • 16.3.26. Sanofi SA
    • 16.3.27. Takeda Pharmaceutical Company Limited
    • 16.3.28. Teva Pharmaceutical Industries Ltd.
    • 16.3.29. UCB S.A.
    • 16.3.30. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-RHEUMATICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJOGREN'S SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJOGREN'S SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJOGREN'S SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJOGREN'S SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJOGREN'S SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJOGREN'S SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)

TABL